The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial
<p>Abstract</p> <p>Background</p> <p>Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-12-01
|
| Series: | Trials |
| Online Access: | http://www.trialsjournal.com/content/11/1/122 |
| _version_ | 1818835893080817664 |
|---|---|
| author | Kim Sang-Hyun Seo Jae-Bin Chung Woo-Young Park Kyungil Zo Joo-Hee Kim Myung-A Park Young-Bae |
| author_facet | Kim Sang-Hyun Seo Jae-Bin Chung Woo-Young Park Kyungil Zo Joo-Hee Kim Myung-A Park Young-Bae |
| author_sort | Kim Sang-Hyun |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clearly defined and debatable. Therefore additional prophylactic pretreatments are needed.</p> <p>Methods/Design</p> <p>The present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.</p> <p>Discussion</p> <p>As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.</p> <p>Trial registration</p> <p>NCT01165567</p> |
| first_indexed | 2024-12-19T02:57:56Z |
| format | Article |
| id | doaj.art-74b5762908a54cc09591138de245ef2c |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-12-19T02:57:56Z |
| publishDate | 2010-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-74b5762908a54cc09591138de245ef2c2022-12-21T20:38:18ZengBMCTrials1745-62152010-12-0111112210.1186/1745-6215-11-122The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trialKim Sang-HyunSeo Jae-BinChung Woo-YoungPark KyungilZo Joo-HeeKim Myung-APark Young-Bae<p>Abstract</p> <p>Background</p> <p>Contrast-induced nephropathy (CIN) is a serious clinical problem associated with increased morbidity and mortality, particularly in patients with chronic renal insufficiency. Although some agents including hydration with saline are being prescribed to prevent renal deterioration in these high risk patients, their efficacy is not clearly defined and debatable. Therefore additional prophylactic pretreatments are needed.</p> <p>Methods/Design</p> <p>The present study aims to investigate differences in occurrence of CIN after sarpogrelate premedication in patients with chronic kidney disease (CKD). 268 participants, aged 20-85 years with a clinical diagnosis of CKD will be recruited. They will be randomly allocated to one of two conditions: (i) routine treatment without sarpogrelate, and (ii) routine treatment with sarpogrelate (a fixed-flexible dose of 300 mg/day). The primary outcome is the occurrence of CIN during 4 weeks after receiving contrast agent.</p> <p>Discussion</p> <p>As of May 2010, there were no registered trials evaluating the therapeutic potentials of sarpogrelate in preventing for CIN. If sarpogrelate decreases the worsening of renal function and occurrence of CIN, it will provide a safe, easy and inexpensive treatment option.</p> <p>Trial registration</p> <p>NCT01165567</p>http://www.trialsjournal.com/content/11/1/122 |
| spellingShingle | Kim Sang-Hyun Seo Jae-Bin Chung Woo-Young Park Kyungil Zo Joo-Hee Kim Myung-A Park Young-Bae The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial Trials |
| title | The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial |
| title_full | The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial |
| title_fullStr | The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial |
| title_full_unstemmed | The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial |
| title_short | The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial |
| title_sort | prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease a study protocol for a prospective randomized controlled clinical trial |
| url | http://www.trialsjournal.com/content/11/1/122 |
| work_keys_str_mv | AT kimsanghyun thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT seojaebin thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT chungwooyoung thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT parkkyungil thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT zojoohee thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT kimmyunga thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT parkyoungbae thepreventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT kimsanghyun preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT seojaebin preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT chungwooyoung preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT parkkyungil preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT zojoohee preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT kimmyunga preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial AT parkyoungbae preventionofcontrastinducednephropathybysarpogrelateinpatientswithchronickidneydiseaseastudyprotocolforaprospectiverandomizedcontrolledclinicaltrial |